Santersus AG announced today the completion of a Series A financing round led by Norcliffe Capital, with participation from Terumo Ventures.
While the company did not disclose the amount raised. It noted that the funds will propel its lead device, NucleoCapture, into pivotal clinical development while accelerating the company’s broader pipeline.
Concurrent with the financing, Santersus entered a strategic collaboration with Terumo Blood and Cell Technologies. The partnership aims to combine Santersus’ NucleoCapture—a blood purification device designed to remove harmful neutrophil extracellular traps (NETs)—with Terumo’s established Spectra Optia Apheresis System.
NucleoCapture has previously received US Food and Drug Administration (FDA) Breakthrough Device Designation for sepsis.
Pivotal Clinical Trials on the Horizon
Under the collaboration, Santersus will lead a pivotal multinational clinical trial for sepsis, named NUC-CAP, across the US, UK, Switzerland, and Europe. The Series A funding will also support preparations for a pivotal trial in systemic lupus erythematosus (SLE), for which the device holds a second FDA Breakthrough Designation.
Beyond critical care, Santersus is advancing its technology into new areas. This includes programs in solid-organ transplantation—aiming to repair donor livers and prevent lung transplant complications—and an early-stage exploratory study in Alzheimer’s disease to assess amyloid removal. These initiatives mark Santersus’s transition into a late-stage, multi-indication clinical development company.
